The United States Food and Drug Administration (FDA) has approved United States-based Vanda Pharmaceuticals Inc's (Nasdaq: VNDA) HETLIOZ (tasimelteon) capsule and liquid formulations intended for the treatment of adults and children, respectively, with night-time sleep disturbances associated with Smith-Magenis Syndrome (SMS), it was reported on Tuesday.
The product is the first FDA-approved medication for patients with SMS. HETLIOZ capsules will immediately be available for adults with SMS, while the HETLIOZ LQ liquid formulation, for children with SMS is likely to be offered in the first quarter of 2021.
The approval was based on a single placebo-controlled efficacy study in this disorder that studied both adults with SMS taking the HETLIOZ capsule and children with SMS taking the liquid formulation. The safety profile of HETLIOZ in this study was similar to those seen in HETLIOZ studies earlier conducted for the treatment of Non-24-Hour Sleep-Wake Disorder, and was similar between adults and children with SMS.
Patients with SMS present with a number of physical, mental and behavioural problems. The most common symptom of SMS is a severe sleep disorder associated with significant disruption in the lives of patients and their families.
ViiV Healthcare wins FDA approval for HIV treatment Cabenuva
Incyte granted FDA priority review for retifanlimab BLA for SCAC
ALung Technologies' FDA approved Hemolung RAS used in treating COVID-19 patients
Menarini Group's ELZONRIS (tagraxofusp) receives European Commission marketing authorisation
Brigham Young University announces alcohol free Disinfect & Shield kills COVID-19 on contact
Johnson & Johnson expected to have 100 million COVID-19 vaccines doses for US by April 2021
FDA Grants Priority Review to Genentech's Esbriet for Unclassifiable Interstitial Lung Disease
Turn Therapeutics Authorized to Start Human Trial for COVID-19 Therapeutic Candidate
Enhertu Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer
US FDA accepts for review Impel NeuroPharma's 5O5(b)(2) New Drug Application for INP104
LumiraDx receives approval of its SARS-CoV-2 Antigen Test Authorization in Japan and Brazil
Qiagen Plans 1Q21 Resubmit of EUA Submission in the US for QIAreach SARS-CoV-2 Antigen Test